Health

STAT+: Pharmalittle: We’re reading about U.S.-funded psychedelic trials, an AstraZeneca R&D center, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 06/10/2026, 14:37:23 UTC.

Briefings

The provided evidence details the U.S. government's $50 million investment in ibogaine clinical trials for opioid addiction and PTSD, alongside AstraZeneca's expansion of its Cambridge, Massachusetts R&D center to 570,000 square feet under a $1 billion state investment program. The article notes the Trump administration's executive order from April 2026 and the FDA's public docket opening on November 20, 2026, for trial feedback. Key facts include the specific drug (ibogaine), the number of trials (first government-funded), and the location (Cambridge, MA). Uncertainty remains regarding the exact number of trial participants and the specific outcomes of the trials, as the evidence focuses on the administrative and infrastructure setup rather than clinical results.

Key points

• The U.S. government has committed $50 million to fund the first clinical trials of ibogaine for opioid addiction and post-traumatic stress disorder, following an April 2026 executive order.
• AstraZeneca opened a 570,000 square-foot R&D center in Cambridge, Massachusetts, as part of a $1 billion state investment program launched in 2024.

Context and limitations

The evidence covers administrative and infrastructure details but does not provide clinical trial outcomes, participant numbers, or specific safety results.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 07/10/2026, 08:19:56 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidnzc2obl5356fbclhdf6vpeyghdptthhzg6kphkmezpjsfzwkn3m